{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:00:15Z","timestamp":1785495615245,"version":"3.56.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) has been administered for graft-versus-host disease (GVHD) prophylaxis of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in recent years. Varied doses of ATG and PTCy were applied in multiple studies with promising outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analyzed 51 consecutive leukemia patients who underwent haplo-HSCT with the joint use of low-dose ATG (27 patients with 7.5 mg\/Kg and 24 patients with 5 mg\/Kg) and PTCy (29 mg\/Kg) for GVHD prophylaxis in our center. The impact of different ATG doses and absolute lymphocyte count (ALC) before ATG infusion was also evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 100-day cumulative incidences (CIs) of grade I-IV, II-IV and III-IV acute GVHD of the whole cohort were 42.9%, 34.7% and 12.2%, respectively. The 2-year CIs of overall and moderate-to-severe chronic GVHD were 44.7% and 27.7%, respectively. The 2-year overall survival, disease-free survival, non-relapse mortality and CI of relapse were 66.7%, 54.8%, 25.5% and 19.7%, respectively. Between 7.5 and 5 mg\/Kg ATG groups, no significant difference on CIs of acute GVHD was observed. Interestingly, pre-ATG ALC impacted the occurrence of acute GVHD. With a cutoff point of 0.585\u00d7109\/L, low ALC group showed reduced CIs of grade I-IV (16.7% versus 58.0%, p=0.01), II-IV (16.7% versus 45.1%, p=0.06) and III-IV (0 versus 19.4%, p=0.05) acute GVHD as compared to high ALC group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results suggested that this low-dose ATG\/PTCy regimen was feasible and pre-ATG ALC levels could influence the occurrence of acute GVHD in this regimen.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1569149","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:23:49Z","timestamp":1749446629000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Low-dose ATG\/PTCy for graft-versus-host disease prevention in haploidentical transplantation: a single-center experience"],"prefix":"10.3389","volume":"15","author":[{"given":"Jian","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangbiao","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: A multicenter, prospective study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.191","article-title":"Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: A randomized trial","volume":"49","author":"Wang","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological Malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30540","article-title":"Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: long-term outcomes of a prospective randomized trial","volume":"123","author":"Chang","year":"2017","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2012.715243","article-title":"Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation","volume":"14","author":"Bosch","year":"2012","journal-title":"Cytotherapy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1356152","article-title":"Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF\/ATG induced GVHD protective activity and improve haploidentical transplant outcomes","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0813-9","article-title":"Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-hsct results in very low rates of GVHD","volume":"55","author":"Salas","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.07.008","article-title":"Reduced-intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological Malignancies","volume":"24","author":"Law","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0053-9","article-title":"Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation","volume":"53","author":"Deotare","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13230","article-title":"Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants","volume":"102","author":"Prem","year":"2019","journal-title":"Eur J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.01.005","article-title":"Sequential conditioning with thiotepa in T cell-replete hematopoietic stem cell transplantation for the treatment of refractory hematologic Malignancies: comparison with matched related, haplo-mismatched, and unrelated donors","volume":"24","author":"Dulery","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00771-w","article-title":"Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic Malignancies: A prospective, multicenter, randomized controlled trial","volume":"13","author":"Zu","year":"2023","journal-title":"Blood Cancer J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0382-3","article-title":"Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic Malignancies: A prospective, phase II study","volume":"54","author":"Yang","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-019-9594-7","article-title":"Comparison of the clinical outcomes of hematologic Malignancies after myeloablative haploidentical transplantation with G-CSF\/ATG and posttransplant cyclophosphamide: results from the Chinese bone marrow transplantation registry group (CBMTRG)","volume":"63","author":"Tang","year":"2019","journal-title":"Sci China Life Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247296","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia","volume":"106","author":"Arnon","year":"2021","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151779","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant","volume":"102","author":"Ruggeri","year":"2017","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1252879","article-title":"Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: A large sample, long-term follow-up retrospective study","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27761","article-title":"Long-Term Follow-up of Haploidentical Hematopoietic Stem Cell Transplantation without in Vitro T Cell Depletion for the Treatment of Leukemia Nine Years of Experience at a Single Center","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12916-019-1393-7","article-title":"Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: A multicenter randomized study","volume":"17","author":"Lin","year":"2019","journal-title":"BMC Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0214-6","article-title":"Population pharmacokinetic modeling of thymoglobulin(\u00ae) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing","volume":"54","author":"Admiraal","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.065","article-title":"Rabbit antithymocyte globulin serum levels: factors impacting the levels and clinical outcomes impacted by the levels","volume":"25","author":"Jamani","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01252-4","article-title":"Population pharmacokinetics of total rabbit anti-thymocyte globulin in non-obese adult patients undergoing hematopoietic cell transplantation for hematologic Malignancy","volume":"62","author":"Takahashi","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.08.029","article-title":"Optimizing antithymocyte globulin dosing for unrelated donor allogeneic hematopoietic cell transplantation based on recipient absolute lymphocyte count","volume":"24","author":"Kennedy","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(17)30029-7","article-title":"Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: A multicentre, retrospective, pharmacodynamic cohort analysis","volume":"4","author":"Admiraal","year":"2017","journal-title":"Lancet Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.06.005","article-title":"Preconditioning absolute lymphocyte count and transplantation outcomes in matched related donor allogeneic hematopoietic stem cell transplantation recipients with reduced-intensity conditioning and antithymocyte globulin treatment","volume":"26","author":"Woo","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.02.026","article-title":"Does lymphocyte count impact dosing of anti-thymocyte globulin in unrelated donor stem cell transplantation","volume":"26","author":"Heelan","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012133","article-title":"Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT","volume":"8","author":"Sanz","year":"2024","journal-title":"Blood Adv"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.316","article-title":"Outcomes after bone marrow versus peripheral blood haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis","volume":"30","author":"Amin","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1569149\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:23:50Z","timestamp":1749446630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1569149\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":30,"alternative-id":["10.3389\/fonc.2025.1569149"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1569149","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"article-number":"1569149"}}